Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy (Clinical and Translational Oncology, (2020), 22, 4, (603-611), 10.1007/s12094-019-02166-z)

A. Passaro; P. Mancuso; S. Gandini; G. Spitaleri; V. Labanca; E. Guerini-Rocco; M. Barberis; C. Catania; E. Del Signore; F. de Marinis; F. Bertolini

ArticleOPEN ACCESS

Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy (Clinical and Translational Oncology, (2020), 22, 4, (603-611), 10.1007/s12094-019-02166-z)

Clinical and Translational Oncology

DOI: 10.1007/s12094-019-02198-5

0Citations

6Readers

Abstract

Acknowledgements section was missing in the original published version. The Acknowledgement section read as follows: Acknowledgements FB supported by AIRC IG 20109.

Cite

CITATION STYLE

APA

Passaro, A., Mancuso, P., Gandini, S., Spitaleri, G., Labanca, V., Guerini-Rocco, E., … Bertolini, F. (2020, April 1). Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy (Clinical and Translational Oncology, (2020), 22, 4, (603-611), 10.1007/s12094-019-02166-z). Clinical and Translational Oncology. Springer. https://doi.org/10.1007/s12094-019-02198-5

Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy (Clinical and Translational Oncology, (2020), 22, 4, (603-611), 10.1007/s12094-019-02166-z)

Abstract

Cite

Register to see more suggestions